Laboratorios Farmaceuticos ROVI SA banner

Laboratorios Farmaceuticos ROVI SA
MAD:ROVI

Watchlist Manager
Laboratorios Farmaceuticos ROVI SA Logo
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
Watchlist
Price: 85.35 EUR -0.06% Market Closed
Market Cap: €4.4B

EV/EBITDA

20.2
Current
50%
More Expensive
vs 3-y average of 13.4

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
20.2
=
Enterprise Value
€4.1B
/
EBITDA
€216.2m

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
20.2
=
Enterprise Value
€4.1B
/
EBITDA
€216.2m

Valuation Scenarios

Laboratorios Farmaceuticos ROVI SA is trading above its 3-year average

If EV/EBITDA returns to its 3-Year Average (13.4), the stock would be worth €56.75 (34% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-52%
Maximum Upside
No Upside Scenarios
Average Downside
39%
Scenario EV/EBITDA Value Implied Price Upside/Downside
Current Multiple 20.2 €85.35
0%
3-Year Average 13.4 €56.75
-34%
5-Year Average 13.5 €57.25
-33%
Industry Average 12.9 €54.41
-36%
Country Average 9.7 €41.07
-52%

Forward EV/EBITDA
Today’s price vs future ebitda

Today's Enterprise Value EBITDA Forward EV/EBITDA
€4.1B
/
Jan 2026
€216.2m
=
20.2
Current
€4.1B
/
Dec 2026
€240.2m
=
17.2
Forward
€4.1B
/
Dec 2027
€325.9m
=
12.7
Forward
€4.1B
/
Dec 2028
€369m
=
11.2
Forward

Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.

Peer Comparison

All Multiples
EV/EBITDA
P/E
All Countries
Close
Market Cap EV/EBITDA P/E
ES
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
4.4B EUR 20.2 31.1
US
Eli Lilly and Co
NYSE:LLY
870.6B USD 28.5 42.2
US
Johnson & Johnson
NYSE:JNJ
544.4B USD 16.6 25.9
CH
Roche Holding AG
SIX:ROG
248.4B CHF 11.6 19.6
UK
AstraZeneca PLC
LSE:AZN
225.4B GBP 16.2 29.2
CH
Novartis AG
SIX:NOVN
222.8B CHF 12.4 20
US
Merck & Co Inc
NYSE:MRK
279.4B USD 9.6 15.3
IE
Endo International PLC
LSE:0Y5F
244.4B USD 386.8 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 8 10.8
US
Pfizer Inc
NYSE:PFE
152.4B USD 7.6 19.6
US
Bristol-Myers Squibb Co
NYSE:BMY
118.4B USD 7.1 16.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ES
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
Average EV/EBITDA: 47.7
20.2
20%
1
US
Eli Lilly and Co
NYSE:LLY
28.5
21%
1.4
US
Johnson & Johnson
NYSE:JNJ
16.6
8%
2.1
CH
Roche Holding AG
SIX:ROG
11.6
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
16.2
12%
1.3
CH
Novartis AG
SIX:NOVN
12.4
5%
2.5
US
Merck & Co Inc
NYSE:MRK
9.6
4%
2.4
IE
E
Endo International PLC
LSE:0Y5F
386.8
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8
2%
4
US
Pfizer Inc
NYSE:PFE
7.6
-8%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.1
-10%
N/A

Market Distribution

Higher than 76% of companies in Spain
Percentile
76th
Based on 638 companies
76th percentile
20.2
Low
0 — 6.5
Typical Range
6.5 — 15.3
High
15.3 —
Distribution Statistics
Spain
Min 0
30th Percentile 6.5
Median 9.7
70th Percentile 15.3
Max 700.4

Laboratorios Farmaceuticos ROVI SA
Glance View

Laboratorios Farmacéuticos ROVI SA has carved a niche for itself in the pharmaceutical industry through its focus on researching, developing, manufacturing, and marketing a broad range of small molecule drugs and specialized products. Founded in Spain, ROVI has channeled its efforts towards creating innovative solutions in the healthcare sector, with heparin-based products emerging as a cornerstone of its portfolio. The company's operational model is built on vertical integration, allowing it to control the entire lifecycle of its offerings, from production to commercialization. This approach not only ensures quality and compliance with stringent regulatory standards but also enables ROVI to adapt nimbly to market demands and leverage its proprietary science to secure a competitive edge. The revenue streams of ROVI are diversified across its proprietary products, contract manufacturing services, and its portfolio of licensed products. A significant portion of revenue stems from its commitment to injectable drug products like Bemiparin, a low molecular weight heparin, which has found a foothold in various international markets. Moreover, ROVI capitalizes on partnerships and alliances with major pharmaceutical giants, augmenting its contract manufacturing capabilities and tapping into more extensive distribution networks. Not resting on its laurels, ROVI invests heavily in research and development to fortify its pipeline with innovative formulations, thus ensuring sustained growth and a resilient positioning in the global pharmaceutical landscape. This blend of strategic partnerships, internal innovation, and market-responsive production underscores ROVI's business model and revenue generation prowess.

ROVI Intrinsic Value
69.81 EUR
Overvaluation 18%
Intrinsic Value
Price €85.35
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett